SEAPORT THERAPEUTICS INC
SPTXNASDAQTrading Snapshot
- Day Range
- $23.57 – $23.93
- 52-Week Range
- $14.85 – $24.48
- Volume
- $3.73B
- Avg Volume
- $3.32B
- Shares Outstanding
- 53.5M
- Next Earnings
- Sep 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $145M
- Last Q Revenue
- $37M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own SPTX
- ✓High-growth profile — revenue up -8.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SEAPORT THERAPEUTICS INC
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation
Seaport Therapeutics: Glyph platform de-risks prodrug delivery; BUOY-1 MDD data H1 2027, GAD Phase 2a H2 2026. Click here to read my analysis.
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate
Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(1.78) per share which missed the analyst consensus estimate of $(0.65) by 173.85 percent. This is a 72.19 percent increase over losses of $(6.40) per
HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $50.